dose dense MVAC with pegylated GCSF

TERMINATED · PHASE2 · Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Neoadjuvant Chemotherapy

Poor accrual due to increased use of alternative neoadjuvant treatment options.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.